208 related articles for article (PubMed ID: 1515646)
1. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
[TBL] [Abstract][Full Text] [Related]
3. New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells.
Okabe M; Uehara M
Leuk Lymphoma; 1993 Dec; 12(1-2):41-9. PubMed ID: 8161936
[TBL] [Abstract][Full Text] [Related]
4. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
[TBL] [Abstract][Full Text] [Related]
5. Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells.
Okabe M; Kawamura K; Miyagishima T; Itaya T; Goodwyn D; Shoji M; Vogler WR; Sakurada K; Uehara M; Miyazaki T
Leuk Res; 1994 Mar; 18(3):213-20. PubMed ID: 7511193
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Honma Y; Matsuo Y; Hayashi Y; Omura S
Int J Cancer; 1995 Mar; 60(5):685-8. PubMed ID: 7860143
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells.
Okabe M; Uehara Y; Noshima T; Itaya T; Kunieda Y; Kurosawa M
Leuk Res; 1994 Nov; 18(11):867-73. PubMed ID: 7967714
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
9. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
10. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.
Riordan FA; Bravery CA; Mengubas K; Ray N; Borthwick NJ; Akbar AN; Hart SM; Hoffbrand AV; Mehta AB; Wickremasinghe RG
Oncogene; 1998 Mar; 16(12):1533-42. PubMed ID: 9569020
[TBL] [Abstract][Full Text] [Related]
11. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
12. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Honma Y; Okabe-Kado J; Hozumi M; Uehara Y; Mizuno S
Cancer Res; 1989 Jan; 49(2):331-4. PubMed ID: 2910452
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.
Laneuville P; Sun G; Timm M; Vekemans M
Blood; 1992 Oct; 80(7):1788-97. PubMed ID: 1327283
[TBL] [Abstract][Full Text] [Related]
14. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
15. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro.
Fukazawa H; Li PM; Yamamoto C; Murakami Y; Mizuno S; Uehara Y
Biochem Pharmacol; 1991 Oct; 42(9):1661-71. PubMed ID: 1656993
[TBL] [Abstract][Full Text] [Related]
17. Control of growth and differentiation of Philadelphia chromosome-positive leukemia cells by tyrosine kinase inhibitors.
Honma Y; Kasukabe T; Hozumi M
Tohoku J Exp Med; 1992 Oct; 168(2):387-91. PubMed ID: 1306324
[TBL] [Abstract][Full Text] [Related]
18. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
20. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.
Anafi M; Gazit A; Zehavi A; Ben-Neriah Y; Levitzki A
Blood; 1993 Dec; 82(12):3524-9. PubMed ID: 7505115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
